Robert R Strieter Deceased401 Oakbrook Dr, Ann Arbor, MI 48103

6491906, Dec 10, 2002

Dec 9, 1998

09/213383

Robert M. Strieter - Ann Arbor MI
Peter J. Polverini - Ann Arbor MI
Steven L. Kunkel - Ann Arbor MI

The Regents of the University of Michigan - Ann Arbor MI

A01N 6300

424 932, 4353201, 435325, 424 852, 4241991, 514 44

Disclosed are various discoveries concerning the angiogenic and angiostatic properties of the CXC chemokines, including the finding that the ELR motif controls the ability of these molecules to induce angiogenesis. Aspects of the invention include, for example, the identification of IP-10, MIG and certain IL-8 analogues as angiostatic agents, and their use in inhibiting angiogenesis in various systems.

6719969, Apr 13, 2004

Aug 4, 2000

09/632531

Cory M. Hogaboam - Ann Arbor MI
Kenneth J. Simpson - Edinburgh, GB
Nicholas W. Lukacs - Brighton MI
Steven L. Kunkel - Ann Arbor MI
Lisa M. Colletti - Webberville MI
Robert M. Strieter - Sherman Oaks CA

The Regents of The University of Michigan - Ann Arbor MI
University Court of The University of Edinburgh

A61K 3820

424 852, 424 851, 424 931, 424 9321, 514 12, 514 44, 514893, 530350

Disclosed is the surprising discovery that CXC chemokines function to induce rapid hepatocyte proliferation and liver regeneration after injury. The invention thus provides a range of compositions and methods for use in treating liver injury, including those suitable for treating acetaminophen overdose outside the therapeutic window for N-acetyl-cysteine treatment, and those that limit the hepatotoxic side-effects of gene therapy regimens.

7052676, May 30, 2006

Sep 20, 2001

09/961696

David M. Markovitz - Ann Arbor MI, US
Brian R. Lane - Ann Arbor MI, US
Peter J. Polverini - Falcon Heights MN, US
Robert M. Strieter - Sherman Oaks CA, US

The Regents of the University of Michigan - Ann Arbor MI

A61K 49/00

424 92, 435 5

Methods are provided for inhibiting or suppressing viral replication in an infected host cell. More specifically, methods are provided for inhibiting or suppressing viral replication in an infected host cell by administering compounds that interfere with the binding of C-X-C chemokines to C-X-C chemokine receptors. Such methods are advantageous for treating viral infections such as human immunodefeciency virus infections.

7265083, Sep 4, 2007

Mar 21, 2002

10/104755

Robert M. Strieter - Ann Arbor MI, US
Steven L. Kunkel - Ann Arbor MI, US

The Regents of The University of Michigan - Ann Arbor MI

A61K 38/00
C12P 21/06
C12N 5/00
C12N 15/00
C12N 15/63
C07K 2/00
C07K 1/00

514 2, 435 691, 4353201, 435325, 435455, 530300, 530350, 530351

Disclosed are various discoveries concerning the angiogenic and angiostatic properties of the CXC chemokines, including the finding that the ELR motif controls the ability of these molecules to induce angiogenesis. Aspects of the invention include, for example, the identification of IP-10, MIG and certain IL-8 analogues as angiostatic agents, and their use in inhibiting angiogenesis in various systems.

8114608, Feb 14, 2012

Nov 30, 2007

12/516912

Borna Mehrad - Charlottesville VA, US
Marie D. Burdick - Charlottesville VA, US
David A. Zisman - Santa Barbara CA, US
Michael P. Keane - Dublin, IE
John A. Belperio - Los Angeles CA, US
Robert M. Strieter - Charlottesville VA, US

University of Virginia Patent Foundation - Charlottesville VA

G01N 33/53

435 71, 435 72, 436518

The present invention provides compositions and methods for diagnosing and treating fibrotic lung disease.

8216796, Jul 10, 2012

Dec 15, 2011

13/327025

Borna Mehrad - Charlottesville VA, US
Marie D. Burdick - Charlottesville VA, US
David A. Zisman - Santa Barbara CA, US
Michael P. Keane - Dublin, IE
John A. Belperio - Los Angeles CA, US
Robert M. Strieter - Charlottesville VA, US

University of Virginia Patent Foundation - Charlottesville VA

G01N 33/53

435 71, 435 72

The present invention provides compositions and methods for diagnosing and treating fibrotic lung disease. In one embodiment the diagnostic method comprises determining the amount of circulating CXCL-12 in a patient relative to a control.

2009001, Jan 8, 2009

Aug 15, 2005

11/662994

Jozef Van Damme - Brussel, BE
Paul Proost - Lubbeek, BE
Sofie Struyf - Wilsele, BE
Robert Strieter - Charlottesville VA, US
Marie D. Burdick - Charlottesville VA, US

K.U. LEUVEN RESEARCH & DEVELOPMENT - Leuven
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA

A61K 38/16
A61K 38/08
C12P 21/00
C07K 7/08
A61P 35/00
C07K 14/00
C07K 7/06
A61K 38/10

514 12, 514 15, 514 14, 435 711, 530328, 530327, 530326, 530325, 530324

The present invention provides novel inhibitors of angiogenesis. The invention relates to PF4var1 and fragments and modifications thereof with anti-angiogenic activity. Therefore, the present invention relates to the use of said proteins and peptides as a medicine, more in particular for the treatment or prevention of angiogenesis or for the manufacture of a medicament for the prevention or treatment of angiogenic diseases. The invention also provides pharmaceutical compositions comprising said proteins and peptides and method of preventing or treating angiogenic disorders.

2012032, Dec 20, 2012

Feb 18, 2011

13/579581

Molly A. Hughes - Charlottesville VA, US
Robert M. Strieter - Charlottesville VA, US

UNIVERSITY OF VIRGINIA PATENT FOUNDATION - Charlottesville VA

A01N 37/46
A61K 39/07
A01N 25/34
A61K 38/19
A01P 1/00
A61P 31/04
A61K 9/00
C07K 14/32

424405, 424400, 4241901, 530350, 514 23, 514 24

The present invention provides proteins with antimicrobial activity, and methods for treating subjects by administering the proteins. In particular, the invention provides methods for treating and/or preventing microbial diseases and infections. The present invention further provides the target for these antimicrobial agents, as well as assays for identifying regulators of the target.